http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1636264-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4208 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42 |
| filingDate | 2004-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21de6793e990ea4ef4e3d0db4066002b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1cd5592c3478d06295f7fb8808c0195 |
| publicationDate | 2006-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1636264-A2 |
| titleOfInvention | Tumour necrosis factor receptor molecules with reduced immunogenicity |
| abstract | The invention relates to the modification of human soluble tumor necrosis factor receptor type 1 (sTNFR1) to result in sTNFR1 proteins, preferably fusion proteins comprising an immunoglobulin heavy chain constant region (Fc domain) and modified human sTNFR-I. These molecules are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo by elimination or deletion of T-cell epitopes. The invention relates furthermore to T-cell epitope peptides derived from non-modified human sTNFR-I. |
| priorityDate | 2003-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.